NCT04387734

Effects of Ocrevus in Relapsing Multiple Sclerosis

Effects and Mechanisms of Ocrevus on Ambulatory Functions in People With Relapsing Multiple Sclerosis

• Status: Active Not Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 60 (actual)
• Sponsor: Georgia State University · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to test if people with relapsing multiple sclerosis (RMS) can improve ambulatory functions after one-year treatment with Ocrevus in comparison with other Disease Modifying Treatments (DMT). Sixty qualified individuals with RMS will be evenly assigned into two groups: Ocrevus and other DMT. Each group will receive the respective treatment following the FDA regulations over the one-year course. Their ambulatory functions will be assessed five times three months apart. In addition, they will receive brain MRI scans three times six months apart. Their ambulatory functions and MRI measurements will be compared between groups over time to fulfill the purposes of this study.

Conditions

• Relapsing Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	Ocrelizumab	Ocrevus will be administered following the FDA's regulations.
DRUG	Platform	The applications of the platform DMTs will follow the FDA-approved regulations.

Timeline

• Start date: 2021-02-05
• Primary completion: 2025-02-17
• Completion: 2026-04-30
• First posted: 2020-05-14
• Last updated: 2026-04-03

Locations

2 sites across 1 country: United States

Regulatory

• FDA-regulated drug study